Company News

Orthocell Accelerates Global Market Expansion of Striate+™ and Remplir™ With Seven New Regulatory Applications either in progress or planned

July 24, 2024
Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned for its medical device platform products. The Company currently has two products gaining market traction – Striate+™ for guided bone and tissue regeneration, and Remplir™ for peripheral nerve repair.  The global market opportunity for these products is estimated to be in excess of US$3 billion (circa A$4.5 billion), and Orthocell is targeting a 20% market share for both products. Striate+™
  • With Striate+™ gaining excellent traction in the US, Europe/UK and Australia, and approved in Canada, $OCC is accelerating market access into Brazil and Singapore with regulatory approvals anticipated within 6-12 months 
  • Orthocell is working with exclusive global distribution partner BioHorizons, to achieve further Striate+™ regulatory approvals into multiple new large markets
Remplir™
  • Remplir™ is gaining strong traction in Australia with regulatory approval in Singapore anticipated within 6 months and the material US FDA approval expected within 9 months  
  • $OCC is accelerating market expansion of Remplir™ into other new markets with regulatory applications in Canada, Thailand and EU/UK planned for submission in the coming months
Earlier this month, Orthocell announced record revenue in FY24, and a balance sheet of $20.6 million, placing it in a strong position to broaden its commercial footprint and grow product adoption and revenues in existing and new markets. Click here to read the ASX release.